Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.41 |
| ▸ | P4HB | P07237 | 1/20 | 0.40 |
| ▸ | SOAT1 | P35610 | 8/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2908399 | 0.91 | SOAT1 (0.45) | GPR84P4HBSOAT1PTGS2 | |
| SCHEMBL2901189 | 0.91 | SOAT1 (0.45) | GPR84P4HBSOAT1PTGS2 | |
| SCHEMBL12402097 | 0.89 | GPR84 (0.41) | GPR84P4HBSOAT1SMN1; SMN2THRB | |
| SCHEMBL12402081 | 0.84 | P4HB (0.50) | GPR84P4HBSOAT1SMN1; SMN2PTGS2 | |
| SCHEMBL2906255 | 0.78 | TDP1 (0.40) | GPR84SMN1; SMN2THRBHSD17B10 | |
| SCHEMBL2901427 | 0.77 | SOAT1 (0.45) | P4HBSOAT1THRB | |
| SCHEMBL2903559 | 0.76 | CA2 (0.39) | SMN1; SMN2THRBHSD17B10 | |
| SCHEMBL27755813 | 0.76 | SOAT1 (0.50) | P4HBSOAT1SMN1; SMN2HSD17B10PTGS2 | |
| SCHEMBL10909807 | 0.76 | PTGS2 (0.44) | GPR84THRBPTGS2 | |
| SCHEMBL10909011 | 0.76 | PTGS2 (0.44) | GPR84THRBPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9039946-B2 | Reversibly thermochromic compositions | BASF SE (DE) | 2015-05-26 | — | — | US | disclosed |
| EP-1888705-B1 | Reversibly thermochromic compositions | BASF SE (DE) | 2010-08-18 | — | — | EP | disclosed |
| US-20090302284-A1 | Reversibly Thermochromic Compositions | CIBA CORPORATION | 2009-12-10 | — | — | US | disclosed |
| EP-1888705-A1 | REVERSIBLY THERMOCHROMIC COMPOSITIONS | Ciba Specialty Chemicals Holding, Inc. (CH) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006131465-A1 | REVERSIBLY THERMOCHROMIC COMPOSITIONS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2006-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090302284-A1 | Reversibly Thermochromic Compositions | DHCR7, NES, DUT | GPR84 2314/4885P4HB 3355/4885SOAT1 2578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.